mani
experiment
strategi
adopt
experi
protect
cat
fiv
infect
vaccin
success
interest
develop
vaccin
aros
fiv
common
caus
morbid
mortal
pet
cat
felin
viru
provid
model
counterpart
man
human
immunodefici
viru
hiv
effect
vaccin
urgent
requir
halt
current
tragic
pandem
acquir
immunodefici
syndrom
aid
shortli
discoveri
fiv
character
lentiviru
attempt
made
produc
vaccin
success
soon
achiev
rel
simpl
inactiv
viru
inactiv
virusinfect
cell
vaccin
develop
approach
led
introduct
first
commerci
vaccin
fiv
estim
preval
infect
popul
pet
cat
effect
fiv
vaccin
could
signific
influenc
anim
welfar
addit
success
pose
question
whether
similar
strategi
might
produc
effect
vaccin
hiv
mani
candid
hiv
vaccin
construct
number
current
undergo
clinic
trial
human
popul
result
first
phase
iii
trial
design
test
abil
vaccin
base
envelop
surfac
glycoprotein
su
protect
exposur
hiv
highrisk
popul
encourag
much
slow
progress
produc
hiv
vaccin
take
phase
iii
trial
ideal
surrog
host
carri
experi
would
confid
predict
whether
candid
vaccin
inde
protect
would
identifi
correl
protect
even
chimpanze
put
sourc
simian
immunodefici
viru
siv
hiv
origin
deriv
dynam
experiment
hiv
infect
suffici
differ
man
render
model
problemat
siv
plausibl
model
system
test
vaccin
strategi
use
extens
purpos
describ
chapter
although
simian
virus
appear
caus
diseas
natur
hostsvari
primat
speci
africathey
caus
fatal
immunodefici
upon
inocul
asian
macaqu
similar
human
aid
outcom
may
well
mimic
situat
develop
man
yet
coevolv
suffici
hiv
render
viru
less
pathogen
mani
siv
vaccin
test
macaqu
still
consensu
constitut
vaccin
could
serv
exampl
hiv
appar
effect
recent
introduc
commerci
fiv
vaccin
rais
question
good
fiv
compar
model
system
hiv
vaccin
studi
weight
put
result
fiv
vaccin
trial
make
decis
type
hiv
vaccin
test
clinic
trial
man
review
examin
similar
fiv
hiv
make
felin
viru
excel
model
pursu
vaccin
strategi
human
aid
discuss
crucial
issu
must
consid
choic
made
produc
fiv
vaccin
final
discuss
result
experiment
trial
select
fiv
vaccin
might
influenc
develop
vaccin
hiv
similar
fiv
hiv
certainli
differ
two
virus
biolog
natur
histori
thu
fiv
differ
genom
content
organ
hiv
illustr
figur
natur
fiv
transmit
mainli
bite
rather
mucos
surfac
like
hiv
follow
infect
proport
infect
cat
develop
aid
although
mani
individu
develop
termin
diseas
enter
cell
primari
isol
fiv
use
receptor
coreceptor
contrast
use
primari
receptor
chemokin
receptor
includ
coreceptor
howev
despit
differ
virus
critic
target
lymphocyt
outcom
infect
remark
similar
cat
man
present
context
dynam
infect
result
immun
respons
much
alik
follow
infect
either
viru
fiv
abl
provid
valuabl
inform
aid
develop
hiv
vaccin
common
featur
fiv
hiv
rather
differ
guid
us
essenti
requir
success
protect
vaccin
infect
fiv
like
hiv
complex
retroviru
genom
approxim
kb
size
contain
accessori
gene
addit
gag
pol
env
figur
comparison
nucleotid
sequenc
repres
fiv
hiv
sequenc
fiv
petaluma
hiv
reveal
overal
homolog
approxim
gagpol
env
correspond
protein
exhibit
lower
homolog
respect
comparison
made
use
gcg
bestfit
univers
wisconsin
felin
pol
gene
like
hiv
encod
proteas
integras
revers
transcriptas
protein
analog
function
virus
fiv
pol
also
encod
addit
enzym
deoxyuridin
pyrophosphatas
du
found
primat
lentivirus
reduc
cellular
concentr
dutp
prevent
viral
mutat
due
misincorpor
viral
cdna
activ
viral
du
particularli
import
nondivid
cell
macrophag
low
endogen
level
host
enzym
fiv
mutant
lack
du
consequ
unabl
replic
product
macrophag
although
du
absent
hiv
role
assum
hiv
vpr
direct
incorpor
uracil
dna
glycosylas
hiv
virion
therebi
reduc
misincorpor
uracil
facilit
replic
macrophag
fiv
model
aid
vaccin
studi
export
unsplic
singli
splice
viral
rna
nucleu
requir
presenc
rev
encod
hiv
fiv
genom
rev
mediat
nuclear
export
bind
rev
respons
element
rre
fiv
rre
locat
transmembran
tm
protein
env
wherea
hiv
rre
tm
vif
viral
infect
factor
gene
also
common
fiv
hiv
function
similar
way
virus
vif
express
critic
viral
dissemin
vivo
infect
nonpermiss
cell
includ
lymphocyt
macrophag
recent
evid
shown
hiv
vif
act
abrog
effect
cellular
antiretrovir
factor
like
fiv
vif
act
analog
manner
fiv
lack
tat
gene
correspond
transactiv
respons
tar
element
addit
fiv
genom
encod
nef
vpr
vpu
howev
encod
addit
accessori
protein
design
orfa
orfa
initi
consid
tatlik
gene
abil
transactiv
viral
transcript
low
level
howev
share
sever
properti
hiv
vpr
includ
nuclear
local
induct
cell
cycl
arrest
knowledg
genet
structur
fiv
allow
use
viru
mutant
experiment
vaccin
exampl
delet
accessori
gene
orfa
vif
result
product
attenu
virus
util
vaccin
dna
vaccin
also
produc
use
fulllength
molecular
clone
proviru
render
replic
defect
infram
delet
either
revers
transcriptas
integras
gene
natur
fiv
infect
acquir
bite
presum
inocul
viru
virusinfect
cell
saliva
persist
infect
cat
cat
readili
infect
parenter
inocul
viru
exampl
intraven
intraperiton
intramuscular
rout
transmiss
mother
kitten
may
occur
proport
offspr
becom
persist
infect
although
neither
oronas
vener
spread
document
natur
cat
infect
experiment
inocul
viru
nose
mouth
vagina
rectum
viru
recov
semen
follow
natur
experiment
infect
case
inocul
result
infect
lymphoid
myelomonocyt
cell
becom
reservoir
maintain
persist
infect
fiv
close
resembl
hiv
dynam
growth
vivo
thu
first
day
follow
experiment
inocul
viru
grow
dendrit
cell
macrophag
lymphocyt
found
plasma
within
week
level
viru
plasma
provir
dna
blood
mononuclear
cell
rise
period
reach
peak
week
period
mild
moder
clinic
sign
exampl
anorexia
depress
pyrexia
may
observ
associ
initi
uninhibit
growth
viru
condit
gener
subsid
rapidli
although
sign
gener
lymphadenopathi
due
increas
number
size
activ
germin
center
cortex
lymph
node
may
continu
sever
week
month
fall
plasma
viral
load
herald
begin
socal
asymptomat
phase
last
mani
year
mani
case
life
cat
quit
healthi
assum
viru
replic
brought
control
develop
immun
respons
viru
fivspecif
cytotox
tcell
ctl
detect
blood
within
one
week
infect
rather
later
around
time
peak
viru
load
antifiv
antibodi
includ
viru
neutral
antibodi
appear
plasma
anoth
hallmark
earli
fiv
infect
certain
isol
appear
popul
tcell
term
low
phenotyp
b
low
cell
serv
marker
immun
activ
virul
strain
fiv
function
may
contribut
noncytolyt
activ
fiv
mediat
tcell
final
outcom
fiv
infect
follow
experiment
natur
challeng
variabl
asymptomat
phase
plasma
viru
load
stabl
progress
declin
lymphocyt
number
occur
yet
unknown
proport
natur
infect
cat
declin
result
function
immunodefici
lead
clinic
diseas
death
one
experi
cat
infect
kitten
strain
maintain
year
approxim
half
cat
develop
seriou
ultim
fatal
condit
could
ascrib
infect
john
callanan
person
commun
contrast
complet
close
household
pet
cat
observ
period
natur
fiv
spread
slowli
among
cat
appear
caus
signific
diseas
clearli
vaccin
trial
fiv
hiv
efficaci
vaccin
must
measur
capac
vaccin
prevent
infect
rather
diseas
discuss
detail
strain
fiv
differ
virul
virus
high
virul
defin
establish
high
viru
load
caus
reduct
lymphocyt
number
activ
low
tcell
contrast
virus
low
virul
establish
infect
plasma
viral
rna
provir
dna
infecti
viru
may
difficult
detect
virus
caus
declin
tcell
number
induc
rise
low
tcell
although
immun
respons
natur
experiment
fiv
infect
elimin
viru
host
hiv
infect
suffici
power
contain
infect
mani
year
consequ
unreason
believ
qualiti
respons
might
one
emul
vaccin
immun
system
appropri
prime
exposur
effect
control
viru
may
possibl
note
respons
accompani
fiv
infect
presum
play
major
role
inhibit
viral
infect
induct
ctl
viru
neutral
antibodi
although
abil
defin
precis
detail
felin
immun
respons
fairli
rudimentari
rel
lack
reagent
compar
avail
man
macaqu
fact
littl
differ
fiv
siv
hiv
understand
appropri
immun
respons
block
viral
infect
earli
studi
hiv
vaccin
concentr
rais
viru
neutral
antibodi
henc
gener
vaccin
incorpor
su
contain
target
antibodi
consid
desir
includ
antigen
could
induc
antibodi
would
neutral
virus
mani
clade
viru
possibl
later
research
conclud
ctl
crucial
protect
immun
sever
vaccin
approach
develop
includ
peptid
epitop
recogn
appropri
haplotyp
popul
vaccin
might
appli
cycl
opinion
occur
fiv
vaccin
research
unresolv
issu
fiv
hiv
viru
strain
isol
use
sourc
immunogen
vaccin
number
fiv
strain
use
antigen
challeng
virus
includ
virus
differ
antigen
clade
virul
major
consider
develop
vaccin
whether
antigen
variat
viru
isol
target
popul
might
expos
high
rate
mutat
recombin
togeth
select
pressur
appli
antivir
immun
respons
host
lentivirus
might
expect
highli
antigen
variabl
prove
classic
method
antigen
type
virus
viru
neutral
unfortun
hiv
measur
viru
neutral
antibodi
fiv
remain
difficult
earli
studi
neutral
sera
infect
vaccin
cat
fiv
adapt
growth
felin
fibroblast
cell
line
crfk
report
howev
type
crfktropic
probabl
fiv
repres
major
virus
isol
natur
infect
cat
probabl
transmit
field
hayley
hain
margaret
hosi
person
commun
like
neutral
virus
assay
mediat
block
interact
region
su
antibodi
viru
neutral
antibodi
complet
absorb
peptid
repres
loop
robert
osborn
person
commun
cat
vaccin
inactiv
viru
vaccin
high
level
viru
neutral
antibodi
measur
way
protect
challeng
crfktropic
fivpet
partial
protect
antibodi
may
contribut
protect
fivpet
although
known
certain
howev
unlik
antibodi
alon
respons
experi
cat
vaccin
peptid
includ
immunodomin
bcell
epitop
protect
fivpet
find
suggest
immun
mechan
requir
protect
natur
occur
virus
neutral
assay
employ
felin
blood
mononuclear
cell
tcell
line
measur
residu
infect
mbm
gener
consid
appropri
indic
antibodi
activ
may
relev
immun
vivo
howev
serum
viru
neutral
antibodi
titer
system
gener
low
make
interpret
result
difficult
problem
measur
antibodi
way
cat
vaccin
inactiv
viru
virusinfect
cell
resolv
preabsorb
sera
cell
viru
prepar
procedur
appear
remov
anticel
activ
sera
therebi
enhanc
viru
neutral
antibodi
titer
use
techniqu
viru
neutral
antibodi
demonstr
vaccin
cat
clear
whether
activ
oper
vivo
contribut
protect
unresolv
import
issu
hiv
vaccin
whether
clade
relev
vaccin
clade
repres
differ
antigen
type
vaccin
design
includ
antigen
preval
clade
particular
geograph
area
fiv
appear
excel
model
answer
question
fiv
exist
least
clade
subtyp
ae
geograph
area
clade
distinct
thu
analys
fiv
isol
made
itali
uk
found
italian
isol
belong
clade
b
uk
isol
clade
alexandra
mauro
pistello
person
commun
austria
southern
germani
appear
mixtur
two
clade
includ
recombin
curiou
distribut
may
due
pattern
migrat
cat
evolut
fiv
cat
popul
addit
clade
recombin
identifi
throughout
world
unfortun
yet
possibl
resolv
issu
whether
fiv
clade
repres
serotyp
difficulti
antigen
type
use
viru
neutral
describ
indic
may
cladespecif
differ
come
comparison
neutral
virus
repres
five
differ
clade
although
insuffici
isol
examin
provid
comprehens
view
antigen
relationship
potenti
complic
find
typespecif
neutral
within
virus
clade
use
crfkbase
assay
report
antigen
relationship
primari
fiv
isol
predict
technic
difficulti
encount
one
studi
italian
isol
clade
b
confirm
resist
neutral
fail
reveal
correl
behavior
neutral
assay
genet
related
epidemiolog
distribut
experi
uk
clade
virus
similar
alexandra
person
commun
resist
appear
highli
conserv
fiv
infect
cat
neutralizationsensit
viru
result
evolut
neutralizationresist
popul
time
clearli
import
field
studi
urgent
requir
effort
clarifi
pragmat
approach
issu
feasibl
cat
man
macaqu
determin
whether
vaccin
contain
antigen
deriv
one
clade
protect
challeng
viru
anoth
clade
far
done
systemat
way
although
pu
et
al
show
cat
vaccin
inactiv
cell
vaccin
contain
mixtur
clade
protect
effect
challeng
virus
clade
b
c
cat
vaccin
clade
viru
alon
commerci
vaccin
deriv
experiment
vaccin
protect
complet
clade
b
viru
inform
practic
signific
fiv
clade
b
wide
distribut
unit
state
part
europ
gener
result
need
confirm
use
challeng
virus
repres
fiv
clade
crossclad
protect
impli
howev
immunogen
common
among
clade
virul
viru
use
challeng
vaccin
cat
taken
account
assess
vaccin
efficaci
discuss
clear
virul
import
consider
choic
viru
use
vaccin
virul
virus
phenotyp
characterist
make
attract
immunogen
cell
tropism
one
characterist
almost
certainli
import
factor
virul
like
hiv
fiv
tropism
lymphocyt
describ
previous
primari
receptor
fiv
coreceptor
probabl
virus
transmit
natur
accordingli
relev
vaccin
develop
requir
molecul
viru
entri
cell
virus
minor
primari
isol
fiv
well
certain
laboratoryadapt
strain
abl
infect
cell
directli
interact
region
su
protein
although
virus
test
capac
replic
vivo
inocul
cat
establish
lower
viru
load
consequ
consid
less
virul
primari
isol
contrast
consid
hiv
appear
termin
phase
infect
somehow
associ
declin
immun
respons
host
therefor
virul
primari
virus
initi
present
infect
experi
fiv
suggest
fact
virus
enter
cell
use
coreceptor
may
product
immunodefici
rather
caus
relev
review
cat
appear
pressur
fiv
evolv
virus
phenotyp
like
primari
isol
use
receptor
direct
inocul
tropic
fiv
establish
low
viru
load
follow
almost
year
later
emerg
viru
popul
appear
chang
receptor
usag
inocul
kitten
variant
virus
establish
higher
viru
load
parent
viru
similar
follow
infect
primari
isol
consequ
appear
select
pressur
viru
evolv
phenotyp
suit
longterm
surviv
host
associ
receptor
usag
cell
tropism
virul
yet
fulli
determin
import
associ
unravel
great
deal
depend
answer
particularli
choic
virus
includ
vaccin
hiv
fiv
use
challeng
virus
fiv
vaccin
trial
measur
efficaci
often
assert
effect
vaccin
induc
immun
respons
equival
occur
individu
challeng
cognat
infecti
agent
subsequ
recov
problem
defin
type
respons
hiv
fiv
induc
virus
establish
persist
infect
infect
individu
never
recov
even
though
possess
strong
antivir
immun
respons
accordingli
also
argu
sinc
respons
observ
cours
infect
elimin
viru
may
necessarili
indic
type
immun
would
desir
protect
vaccin
protect
afford
inactiv
viru
vaccin
fiv
exploit
determin
immun
correl
vaccineinduc
protect
experi
inactiv
viru
vaccin
manipul
protect
proport
vaccin
cat
allow
comparison
immun
respons
follow
vaccin
result
either
protect
establish
persist
infect
viru
neutral
antibodi
appear
correl
protect
period
immedi
follow
viru
challeng
ctl
induc
earli
vaccin
correl
protect
challeng
month
later
result
suggest
perhap
univers
respons
viru
neutral
antibodi
ctl
induc
benefici
vaccin
compon
import
protect
suggest
result
experi
protect
could
transfer
success
vaccin
cat
either
serum
blood
mononuclear
cell
whether
conclus
experi
inactiv
viru
vaccin
valid
also
type
vaccin
known
sinc
vaccin
inactiv
vaccin
entir
success
yet
possibl
determin
directli
correl
whatev
protect
provid
although
measur
immun
respons
elicit
vaccin
may
give
valuabl
indic
immunogen
vaccin
still
entir
clear
immun
respons
may
protect
broad
rang
cellular
humor
respons
may
requir
specif
antibodi
respons
defin
epitop
may
essenti
furthermor
contribut
protect
made
nonspecif
innat
immun
respons
eg
nk
cell
uncertain
absenc
correl
protect
assess
vaccin
efficaci
possibl
use
challeng
model
choic
appropri
challeng
clearli
import
four
factor
consid
choic
viru
strain
sourc
viru
challeng
rout
dose
inoculum
number
viral
strain
use
efficaci
studi
illustr
tabl
ii
iii
strain
vari
significantli
virul
assess
viral
load
attain
reduct
tlymphocyt
number
follow
challeng
consider
whether
homolog
heterolog
challeng
use
choic
challeng
strain
may
influenc
geographi
exampl
northern
europ
clade
virus
predomin
central
southern
europ
clade
b
virus
common
studi
field
case
fiv
shown
major
infect
cat
rel
high
viral
load
depress
tlymphocyt
count
support
use
pathogen
viru
challeng
strain
vaccin
studi
addit
provid
realist
model
hiv
high
viral
load
suppress
count
typic
seen
infect
patient
felin
model
offer
good
opportun
studi
effect
viral
variat
abil
vaccin
protect
challeng
virus
differ
clade
differ
pathogen
believ
fiv
transmit
mainli
bite
therefor
traumat
transfer
viru
virusinfect
cell
saliva
dilemma
choos
appropri
sourc
viru
balanc
simul
natur
infect
practic
obtain
suitabl
reproduc
inoculum
infect
saliva
use
difficulti
obtain
suffici
quantiti
accept
qualiti
materi
wide
employ
free
viru
infect
cell
grown
cultur
felin
tcell
either
primari
blood
mononuclear
cell
cell
line
use
viru
deriv
molecular
clone
may
prefer
ensur
consist
experi
avoid
viral
attenu
occur
longterm
cultur
vitro
increasingli
viruscontain
plasma
cat
infect
appropri
fiv
strain
use
although
viru
grown
vitro
readili
control
viru
obtain
ex
vivo
may
repres
close
state
viru
transmit
natur
exampl
term
resist
suscept
neutral
antibodi
viru
isol
neg
cat
two
cat
transient
posit
pcr
pbmc
provir
dna
viru
isol
neg
cat
cat
becam
seroposit
cat
posit
pcr
pbmc
provir
dna
one
cat
remain
viru
isol
neg
previous
posit
pcr
pbmc
provir
dna
assess
efficaci
fiv
vaccin
develop
product
use
target
speci
challeng
deliv
manner
relev
rout
infect
natur
transmiss
occur
case
establish
outcom
hous
vaccin
nonvaccin
cat
togeth
healthi
persist
infect
cat
provid
natur
realist
measur
vaccin
efficaci
howev
practic
use
direct
parenter
inocul
viru
employ
attempt
provid
model
sexual
transmiss
hiv
mucos
challeng
fiv
also
use
natur
challeng
clear
advantag
fiv
model
siv
model
ultim
test
vaccin
natur
host
field
condit
possibl
provid
realist
assess
well
vaccin
perform
intend
environ
preval
fiv
quit
high
mani
popul
cat
estim
rang
healthi
pet
cat
popul
small
popul
high
preval
might
suggest
would
easi
test
fiv
vaccin
natur
set
rel
small
number
cat
either
experiment
condit
field
unfortun
case
situat
natur
transmiss
among
pet
cat
field
would
difficult
imposs
obtain
permiss
regulatori
author
carri
experi
keep
pet
shelter
cat
situat
unvaccin
individu
might
infect
appeal
experiment
situat
simul
natur
transmiss
problem
achiev
suffici
high
incid
transmiss
infect
particularli
among
cat
well
social
nonaggress
toward
group
size
need
larg
ensur
statist
meaning
result
portion
vaccin
like
remain
uninfect
follow
challeng
experi
mani
cat
hous
fivinfect
anim
may
remain
uninfect
period
year
howev
case
regular
slow
spread
infect
record
potenti
problem
ensur
test
major
candid
vaccin
must
still
perform
experiment
anim
challeng
viru
administ
artifici
make
experi
realist
consid
use
dose
viru
repres
natur
challeng
use
multipl
lower
dose
viru
hope
vaccin
abl
prevent
infect
experiment
set
robust
challeng
may
like
provid
signific
protect
pet
cat
field
inocul
challeng
viru
discuss
differ
rout
natur
transmiss
fiv
hiv
hiv
transmit
across
mucos
surfac
fiv
spread
mainli
bite
consequ
fiv
serv
model
hiv
vaccin
two
way
first
obviou
model
describ
principl
establish
elicit
protect
natur
challeng
may
abl
appli
hiv
second
model
involv
manipul
fiv
system
attempt
protect
cat
viru
administ
vagin
rectal
rout
natur
mean
transmiss
fiv
may
relev
hiv
cat
may
infect
vagin
rectal
oral
although
mucos
rout
requir
higher
dose
viru
intramuscular
intraperiton
intraven
inocul
produc
persist
infect
infect
may
readili
establish
rectal
vagin
rout
cellassoci
viru
cellfre
viru
agreement
infecti
dose
requir
infect
macaqu
siv
rout
vagin
inocul
effici
rectal
inocul
oronas
administr
least
effect
method
infect
clearli
rout
viral
challeng
may
influenc
abil
vaccin
protect
infect
diseas
infect
intramuscular
intraperiton
rout
requir
rel
low
amount
viru
infect
mucos
infect
either
vagin
rectal
intranasalor
rout
requir
larg
amount
four
log
higher
requir
establish
infect
intraven
intraperiton
rout
implic
differ
hiv
may
similarli
readili
transmit
intraven
drug
use
sexual
transmiss
remain
determin
although
seem
like
whether
vaccin
may
readili
prevent
infect
mucos
compar
parenter
inocul
desir
immun
respons
requir
prevent
infect
almost
certainli
differ
depend
rout
exposur
viru
exampl
result
vaccin
trial
use
mucos
challeng
discuss
dose
challeng
viru
dose
viral
inoculum
use
challeng
typic
chosen
suffici
high
ensur
nonvaccin
control
becom
infect
usual
median
cat
infecti
dose
viru
use
howev
dose
like
far
greater
would
encount
natur
challeng
possibl
therefor
vaccin
trial
carri
use
challeng
dose
may
underestim
potenti
efficaci
vaccin
field
set
content
support
vaccin
trial
matteucci
et
al
perform
popul
feral
cat
privat
shelter
fiv
endem
preval
anim
vaccin
six
dose
fiv
clade
b
paraformaldehydeinactiv
infect
cell
vaccin
observ
period
first
immunis
although
control
anim
becam
infect
vaccin
remain
free
infect
result
contrast
rel
modest
success
obtain
laboratori
cat
use
similar
vaccin
assess
success
vaccin
experi
four
potenti
outcom
may
envisag
vaccin
may
provid
robust
protect
induc
steril
immun
possibl
isol
infecti
viru
detect
viral
rna
provir
dna
polymeras
chain
reaction
pcr
follow
challeng
although
may
provid
steril
immun
vaccin
may
provid
signific
protect
lead
decreas
viral
load
blood
lymphoid
tissu
follow
challeng
altern
vaccin
may
fail
provid
degre
protect
wors
may
actual
enhanc
infect
follow
challeng
exampl
outcom
may
seen
tabl
iiii
mani
vaccin
fail
induc
signific
protect
outcom
even
vaccin
induc
signific
antivir
immun
respons
contrast
degre
protect
achiev
vaccin
fail
activ
one
anoth
arm
specif
immun
respons
find
emphas
need
viral
challeng
assess
vaccin
efficaci
experi
lentivir
vaccin
develop
realiz
qualiti
immun
respons
induc
vaccin
might
insuffici
provid
steril
immun
infect
given
rise
hope
might
control
subsequ
infect
suffici
reduc
transmiss
viru
infect
individu
prevent
progress
declin
diseas
death
confirm
risk
transmiss
reduc
vaccin
possibl
fiv
perfectli
feasibl
quantifi
viru
provir
dna
saliva
surprisingli
littl
work
appear
done
import
subject
worri
result
candid
vaccin
find
infect
enhanc
follow
challeng
outcom
observ
number
differ
type
fiv
vaccin
includ
inactiv
whole
cell
vaccin
envelop
subunit
vaccin
dna
vaccin
encod
viral
envelop
number
potenti
mechan
enhanc
propos
discuss
spite
number
variabl
associ
challeng
system
vaccin
shown
effect
cat
virul
challeng
fiv
given
biolog
similar
two
lentivirus
must
consid
seriou
candid
develop
hiv
vaccin
mind
lesson
learn
cat
result
recent
fiv
vaccin
trial
shown
tabl
iiii
illustr
number
candid
vaccin
develop
earliest
fiv
vaccin
studi
base
viru
infect
cell
inactiv
paraformaldehyd
sinc
mani
approach
tri
includ
peptid
recombin
protein
dna
vaccin
viral
vector
howev
despit
applic
new
technolog
fiv
vaccin
develop
dna
vaccin
shown
earli
promis
inactiv
viru
infect
cell
vaccin
remain
success
whole
inactiv
viru
vaccin
pioneer
yamamoto
colleagu
provid
complet
protect
challeng
homolog
viru
fivpet
anoth
strain
clade
hosi
et
al
confirm
result
show
subsequ
vaccin
although
provid
full
protect
challeng
heterolog
viru
significantli
reduc
viru
load
reason
differ
degre
protect
achiev
challeng
two
virus
entir
clear
discuss
strong
possibl
greater
virul
strain
respons
viru
establish
high
viru
load
might
difficult
protect
vaccin
either
grow
rapidli
follow
infect
establish
infect
cell
access
immun
respons
induc
vaccin
anoth
possibl
explan
two
virus
differ
antigen
crfkbase
neutral
assay
shown
although
fivpet
clade
crossneutr
sera
deriv
cat
infect
either
viru
degre
antigen
strain
specif
third
possibl
mention
previous
fivpet
viru
readili
neutral
particular
antibodi
induc
vaccin
effect
dose
viru
rapidli
reduc
immedi
follow
challeng
virul
viru
indic
phenotyp
incorpor
vaccin
order
provid
effect
protect
virus
prime
candid
howev
earli
attempt
produc
effect
inactiv
viru
vaccin
base
unsuccess
lack
efficaci
ascrib
poor
preserv
su
vaccin
viru
compar
fivpet
cell
attempt
produc
vaccin
contain
particl
high
level
su
molecular
clone
modifi
produc
viru
endocytosi
signal
cytoplasm
tail
env
mutat
therebi
promot
accumul
viru
infect
cell
surfac
incorpor
su
viral
particl
vaccin
deriv
particl
inactiv
paraformaldehyd
provid
partial
protect
virul
challeng
although
formul
two
vaccin
quit
differ
may
signific
improv
efficaci
second
vaccin
due
better
preserv
su
vaccin
viru
particl
howev
degre
protect
achiev
second
vaccin
challeng
markedli
greater
afford
previou
vaccin
base
fivpet
outcom
suggest
factor
qualiti
su
necessari
protect
challeng
virus
high
virul
vaccin
base
inactiv
fivinfect
cell
also
provid
good
protect
materi
attract
commerci
proposit
requir
expens
concentr
purif
contain
full
rang
viral
protein
initi
experi
yamamoto
et
al
obtain
essenti
equival
protect
vaccin
contain
either
paraformaldehydeinactiv
whole
viru
inactiv
infect
cell
vaccin
experi
vaccin
deriv
cell
line
chronic
infect
fivpet
challeng
homolog
viru
administ
intraperiton
rout
develop
approach
vaccin
found
protect
also
anoth
viru
clade
inclus
cell
infect
second
strain
fiv
fivshi
belong
clade
extend
efficaci
vaccin
protect
challeng
three
differ
fiv
strain
fivpet
clade
fivban
clade
b
fivshi
clade
commerci
deriv
vaccin
shown
subsequ
protect
primari
isol
clade
b
common
clade
unit
state
viru
consid
high
virul
caus
reduct
tcell
number
unvaccin
cat
attempt
set
benchmark
vaccin
could
judg
test
abil
commerci
vaccin
protect
challeng
virul
uk
isol
vaccin
fail
provid
steril
protect
cat
regardless
whether
challeng
intramuscular
intraperiton
oronas
rout
rais
question
whether
repres
excess
challeng
studi
uk
field
isol
shown
typic
produc
high
viral
load
depress
tcell
number
appear
repres
howev
clear
factor
may
compromis
abil
vaccin
protect
isol
ideal
vaccin
would
test
panel
wellcharacter
field
isol
unfortun
impract
present
confirm
efficaci
vaccin
contain
fivinfect
cell
provid
matteucci
et
al
vaccin
base
paraformaldehydeinactiv
cell
mbm
felin
lymphoblast
line
infect
protect
cat
challeng
ex
vivo
cellfre
viru
month
vaccin
signific
protect
record
cat
challeng
month
vaccin
indic
durat
immun
short
nevertheless
vaccin
protect
cat
natur
set
period
month
describ
contrast
success
type
inactiv
cell
vaccin
proven
protect
substrat
vaccin
viru
grown
may
effect
efficaci
thu
vaccin
base
paraformaldehydeinactiv
crfk
cell
felin
thymocyt
infect
fail
protect
cat
challeng
homolog
viru
even
alarm
outcom
found
later
trial
vaccin
contain
inactiv
fivinfect
autolog
tcell
rational
experi
fiv
antigen
would
present
mhcmatch
manner
howev
challeng
homolog
viru
found
enhanc
challeng
indic
shorter
period
challeng
appear
viraemia
vaccin
cat
versu
control
similar
result
obtain
giannecchini
et
al
test
four
vaccin
base
inactiv
infect
autolog
lymphoblast
compar
littl
interest
develop
inactiv
viru
vaccin
hiv
despit
efficaci
fiv
vaccin
extrem
success
use
mani
kill
vaccin
human
diseas
main
reason
lack
interest
danger
aris
incomplet
inactiv
infecti
viru
high
cost
product
viru
requir
largescal
use
poor
countri
recent
inactiv
hiv
use
boost
primeboost
vaccin
regim
attempt
protect
macaqu
infect
sivhiv
recombin
viru
shiv
rational
use
inactiv
viru
particl
might
induc
high
level
viru
neutral
antibodi
complement
cellmedi
immun
like
elicit
prime
compon
vaccinia
viru
recombin
express
hiv
siv
structur
protein
vaccin
fail
prevent
infect
challeng
although
viru
load
much
reduc
compar
unvaccin
control
anim
vaccin
macaqu
remain
healthi
period
month
control
develop
aid
within
period
attenu
viru
vaccin
offer
sever
advantag
inactiv
vaccin
rel
inexpens
produc
often
requir
adjuv
efficaci
produc
robust
immun
respons
relev
develop
lentiviru
vaccin
capac
attenu
vaccin
induc
antibodi
cellmedi
immun
respons
virus
tradit
attenu
prolong
passag
cell
cultur
howev
introduct
defin
chang
use
molecular
techniqu
offer
refin
perhap
safer
approach
delet
accessori
lentivir
gene
provid
method
reduc
virul
without
complet
disabl
viru
replic
dissemin
vivo
extens
pursu
siv
model
attempt
produc
nef
delet
siv
vaccin
base
discoveri
number
individu
infect
hiv
variant
delet
nef
show
slow
diseas
progress
although
approach
show
initi
promis
eventu
develop
diseas
vaccin
macaqu
hivinfect
individu
led
obviou
reluct
pursu
vaccin
hiv
opportun
provid
fiv
model
avail
virus
low
virul
test
abil
protect
subsequ
challeng
virul
viru
possibl
fivpet
attenu
prolong
growth
vitro
could
protect
subsequ
virul
challeng
studi
modest
protect
seen
administ
intraven
excel
protect
achiev
intraperiton
challeng
cellfre
cellassoci
vagin
challeng
although
vaccin
unlik
consid
safe
enough
clinic
develop
may
abl
provid
use
insight
viral
determin
pathogenesi
immun
correl
protect
difficulti
encount
use
attenu
viru
vaccin
grow
viral
stock
suffici
titer
vitro
produc
quantiti
requir
vaccin
dna
vaccin
offer
altern
method
explor
immunogen
provirus
render
defect
select
delet
first
success
exampl
approach
use
delet
revers
transcriptas
gene
produc
dna
vaccin
drt
provid
signific
protect
challeng
homolog
viru
fivpet
encourag
hope
vaccin
protect
might
extend
virul
isol
howev
subsequ
studi
fail
demonstr
signific
level
protect
use
provir
dna
vaccin
either
drt
vaccin
similar
vaccin
delet
integras
attempt
improv
level
protect
use
varieti
cytokin
adjuv
primeboost
approach
also
unsuccess
one
promis
result
shown
dna
vaccin
fivppr
use
provir
dna
vaccin
attenu
delet
vif
unfortun
safeti
vaccin
uncertain
possibl
attenu
viru
may
revert
virul
phenotyp
dna
vaccin
develop
widespread
use
one
concern
would
need
address
use
vector
contain
antibiot
resist
gene
system
accomplish
test
fiv
model
minimalist
immunogen
defin
gene
express
midg
construct
encod
fiv
env
felin
lack
unnecessari
vector
sequenc
shown
signific
protect
challeng
experi
dna
vaccin
fiv
mirror
dna
vaccin
siv
viral
pathogen
although
shown
earli
promis
yet
produc
level
protect
use
alon
suggest
may
appli
hiv
led
sever
approach
tri
improv
efficaci
includ
use
cytokin
adjuv
inocul
dna
vaccin
combin
viral
vector
protein
primeboost
approach
use
improv
deliveri
system
alter
codon
usag
improv
express
level
approach
current
also
tri
fiv
improv
efficaci
attain
would
great
valu
develop
lentivir
vaccin
earli
effort
develop
hiv
fiv
vaccin
attempt
induc
protect
neutral
antibodi
although
major
success
experi
fiv
model
use
whole
inactiv
infect
cell
prepar
outlin
experi
also
perform
use
subunit
peptid
vaccin
tabl
iii
larg
unsuccess
inde
result
reflect
great
challeng
face
develop
antigen
induc
potent
broadli
reactiv
antibodi
mediat
protect
hiv
like
success
vaccin
compris
protect
epitop
similar
viru
sinc
major
conform
depend
expect
peptid
immunogen
less
like
achiev
use
envelop
vaccin
met
poor
success
like
due
lack
authent
conform
monom
outcom
seen
fiv
system
rel
poor
efficaci
purifi
vaccin
contrast
robust
protect
provid
whole
inactiv
viru
purifi
prepar
deriv
lack
efficaci
anim
model
howev
appear
lesson
heed
clinic
develop
hiv
vaccin
pursu
great
cost
prototyp
hiv
vaccin
discuss
like
dna
vaccin
vaccin
viral
vector
effect
gener
cellmedi
immun
respons
although
rel
studi
perform
viral
vector
vaccin
fiv
one
effect
vaccin
pathogen
felin
retroviru
felv
canarypox
vector
express
felv
env
gag
protein
cat
immun
prime
canarypox
viru
encod
fiv
env
gagpol
follow
boost
inactiv
fivinfect
cell
vaccin
solidli
protect
homolog
challeng
clade
fivpet
subsequ
challeng
clade
b
fivbang
cat
show
full
partial
protect
idea
combin
vaccin
gener
potent
cellmedi
immun
one
gener
potent
antibodi
respons
one
adopt
effort
develop
effect
human
aid
vaccin
howev
earli
data
phase
ii
clinic
trial
human
primeboost
combin
canarypox
encourag
trial
individu
becam
infect
subsequ
vaccin
show
delay
progress
infect
compar
receiv
placebo
disturb
phenomenon
enhanc
fiv
challeng
follow
vaccin
evidenc
acceler
appear
viraemia
higher
viru
load
increas
proport
cat
becom
infect
compar
control
cat
observ
sever
differ
type
vaccin
effect
recogn
macaqu
vaccin
siv
therefor
known
whether
enhanc
danger
avoid
hiv
vaccin
although
concern
sera
infect
individu
may
amplifi
hiv
infect
vitro
enhanc
activ
serum
suggest
compon
progress
aid
two
plausibl
mechan
advanc
account
enhanc
fiv
infect
vaccin
first
implic
antibodymedi
infect
target
cell
exampl
fc
complement
receptor
experi
evalu
sever
env
product
immunogen
enhanc
produc
cat
vaccin
env
express
vaccinia
recombin
transfer
cat
plasma
vaccin
anim
definit
region
env
might
respons
effect
prove
elus
pancino
sonigo
show
highli
conserv
structur
princip
immunogen
determin
tm
maintain
two
delin
cystein
essenti
viral
infect
suggest
induct
antibodi
region
repres
larg
proport
serum
antifiv
antibodi
infect
cat
might
mechan
evolv
enhanc
viral
entri
growth
howev
induct
antibodi
specif
env
possibl
mechan
involv
evid
experi
enhanc
produc
cat
immun
vaccin
includ
env
consequ
could
elicit
antienv
antibodi
exampl
recombin
gag
vaccin
adjuv
immun
stimul
complex
addit
enhanc
might
due
gener
effector
antibodi
thu
richardson
et
al
show
like
mechan
increas
viral
growth
cat
challeng
expans
activ
lymphocyt
induc
vaccin
dna
env
vaccin
induc
antifiv
antibodi
previou
trial
similar
vaccin
result
enhanc
vaccin
cat
challeng
shortli
vaccin
time
lymphocyt
activ
might
peak
second
trial
attempt
minim
effect
vaccin
cat
challeng
week
final
vaccin
cat
immun
intradermalintramuscular
rout
exhibit
enhanc
infect
challeng
howev
appear
viru
blood
cat
vaccin
target
mesenter
lymph
node
much
acceler
cat
fivspecif
helper
tcell
prolif
respons
cell
suscept
normal
cell
infect
fiv
ex
vivo
although
number
subject
experi
small
result
suggest
activ
fivspecif
tcell
might
suscept
infect
nonspecif
cell
demonstr
hiv
also
possibl
vaccin
result
chang
popul
cell
suscept
infect
exampl
quantiti
distribut
cell
express
receptor
fiv
may
increas
great
concern
welfar
cat
find
enhanc
seen
trial
vaccin
base
inactiv
infect
cell
result
product
commerci
fiv
vaccin
inactiv
cell
vaccin
cat
challeng
week
receiv
third
dose
commerci
vaccin
plasma
viral
load
elev
week
postchalleng
compar
unvaccin
control
viral
load
fell
control
week
postchalleng
earli
rise
suggest
wider
viral
dissemin
establish
viral
reservoir
may
occur
clearli
potenti
enhanc
great
import
use
fiv
vaccin
also
develop
hiv
vaccin
suggest
increas
length
time
follow
vaccin
prior
challeng
may
reduc
risk
enhanc
howev
prevent
exposur
viru
immun
respons
matur
possibl
increas
suscept
infect
declin
seem
unlik
proposit
commerci
vaccin
develop
mucos
vaccin
hiv
undoubtedli
rapidli
grow
area
given
increas
impetu
find
gastrointestin
mucosa
repres
major
viral
reservoir
discuss
much
effort
appli
develop
fiv
model
accommod
challeng
mucos
rout
relev
hiv
degre
protect
vagin
challeng
achiev
vaccin
although
parenter
vaccin
inactiv
viru
vaccin
protect
challeng
homolog
viru
vaccin
cat
significantli
lower
viru
load
control
cat
anoth
approach
recombin
vaccin
consist
alphaviru
replicon
deliv
fiv
gag
env
given
subcutan
induc
serum
mucos
antifiv
antibodi
protect
vagin
challeng
virul
strain
use
bacteria
vector
mucos
vaccin
deliveri
also
area
grow
interest
lentiviru
vaccin
earli
attempt
develop
salmonella
vector
fiv
vaccin
met
modest
success
contrast
recent
trial
recombin
listeria
monocytogen
vector
express
fiv
gag
env
singl
oral
dose
vaccin
provid
signific
protect
vaccin
control
cat
becam
infect
follow
challeng
virul
strain
fiv
vaccin
cat
extrem
low
viru
load
compar
control
suffer
deplet
lymphocyt
intestin
mesenter
lymph
node
found
control
cat
vaccin
trial
use
rectal
challeng
also
carri
mucos
immun
either
su
peptid
inactiv
infect
cell
adjuv
quil
cholera
b
toxin
although
induc
fivspecif
antibodi
tcell
prolifer
protect
cat
rectal
challeng
homolog
viru
success
result
obtain
inactiv
cell
vaccin
immun
target
iliac
lymph
node
rectal
challeng
homolog
cellfre
fivpet
known
whether
differ
outcom
second
trial
due
better
preserv
immunogen
effect
immun
lower
virul
fivpet
challeng
challeng
cellassoci
viru
prove
unexpectedli
ineffici
even
control
cat
vaccin
inactiv
uninfect
cell
suggest
anticel
immun
respons
induc
might
protect
challeng
nonfivspecif
fashion
parenter
challeng
system
success
failur
vaccin
mucos
challeng
could
due
varieti
factor
includ
choic
antigen
deliveri
system
strain
challeng
viru
short
review
discuss
way
develop
fiv
vaccin
approach
drive
forc
behind
mani
attempt
produc
vaccin
could
use
field
prevent
spread
fiv
among
domest
cat
addit
recogn
end
achiev
methodolog
might
well
applic
develop
vaccin
hiv
human
far
success
tantalizingli
close
commerci
vaccin
becom
avail
experiment
vaccin
shown
protect
challeng
natur
set
vaccin
provid
partial
protect
paradox
valuabl
outcom
trial
fiv
vaccin
fail
provid
complet
protect
sever
confound
factor
identifi
resolut
may
provid
basi
effect
vaccin
futur
exampl
commerci
vaccin
found
protect
viru
strain
other
result
may
due
differ
virul
virus
use
challeng
suffici
wellcharacter
fiv
strain
avail
test
reason
anoth
possibl
antigen
differ
virus
avail
larg
number
primari
fiv
isol
differ
clade
around
world
mean
antigen
relationship
individu
virus
clade
might
defin
practic
signific
differ
might
test
directli
experiment
challeng
question
whether
partial
protect
reduc
transmiss
fiv
determin
quantif
viru
saliva
vaccin
challeng
cat
enhanc
infect
follow
vaccin
concern
applic
hiv
vaccin
field
definit
factor
respons
enhanc
necessari
overcom
enhanc
certain
fiv
vaccin
made
despit
opportun
provid
fiv
resolv
issu
undoubtedli
also
appli
hiv
vaccin
develop
felin
model
rel
neglect
aid
research
commun
crucial
problem
arisen
cours
fiv
vaccin
develop
resolv
care
systemat
analysi
viral
host
factor
respons
doubt
given
gener
resourc
mani
problem
could
overcom
central
tenet
product
effect
vaccin
fiv
hiv
could
establish
